| Cvs Pharmacy #06996 | |
| 11601 Springfield Pike, Cincinnati, Ohio 45246 | |
| (513) 851-5063 |
| Name | Cvs Pharmacy #06996 |
|---|---|
| Organization Name | Ohio Cvs Stores Llc |
| Location | 11601 Springfield Pike, Cincinnati, Ohio 45246 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (513) 851-5063 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
In this post in the Management Sciences for Health's (MSH) "Global Health Impact" blog, Scott Kellerman, global technical lead for HIV/AIDS at MSH, discusses USAID's "Every Child Deserves a 5th Birthday" campaign and recent attention to the prevention of mother-to-child transmission (PMTCT) of HIV.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.
› Verified 3 days ago
| NPI Number | 1639272461 |
| Organization Name | OHIO CVS STORES LLC |
| Doing Business As | CVS PHARMACY 06996 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 11601 Springfield Pike, Springdale, OH 45246 |
| Phone Number | 513-851-5063 |
News Archive
In this post in the Management Sciences for Health's (MSH) "Global Health Impact" blog, Scott Kellerman, global technical lead for HIV/AIDS at MSH, discusses USAID's "Every Child Deserves a 5th Birthday" campaign and recent attention to the prevention of mother-to-child transmission (PMTCT) of HIV.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.
› Verified 3 days ago
News Archive
In this post in the Management Sciences for Health's (MSH) "Global Health Impact" blog, Scott Kellerman, global technical lead for HIV/AIDS at MSH, discusses USAID's "Every Child Deserves a 5th Birthday" campaign and recent attention to the prevention of mother-to-child transmission (PMTCT) of HIV.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.
› Verified 3 days ago
Cvs Pharmacy # 07699 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 11611 Hamilton Avenue, Cincinnati, Ohio 45231 Phone: (513) 742-1155 | |
Cvs Pharmacy # 03246 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4840 Glenway Avenue, Cincinnati, Ohio 45238 Phone: (513) 921-0831 | |
Cvs Pharmacy #05426 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9197 Reading Rd, Cincinnati, Ohio 45215 Phone: (513) 733-8550 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10720 Makro Dr, Cincinnati, Ohio 45241 Phone: (513) 272-6050 | |
Cvs Pharmacy #02715 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 17 William Howard Taft Rd, Cincinnati, Ohio 45219 Phone: (513) 569-4301 |